治疗剂量肝素对因 COVID-19 住院患者的治疗效果——回复 - Suppr | 超能文献

Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19-Reply.

作者信息

Goligher Ewan C, Lawler Patrick R, Zarychanski Ryan

机构信息

Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Ontario, Canada.

McGill University Health Centre, Montreal, Quebec, Canada.

出版信息

JAMA. 2023 Aug 1;330(5):472-473. doi: 10.1001/jama.2023.9538.

DOI:10.1001/jama.2023.9538

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19-Reply.治疗剂量肝素对因 COVID-19 住院患者的治疗效果——回复

JAMA. 2023 Aug 1;330(5):472-473. doi: 10.1001/jama.2023.9538.

2

Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19.治疗剂量肝素对因 COVID-19 住院患者的治疗效果

JAMA. 2023 Aug 1;330(5):471-472. doi: 10.1001/jama.2023.9535.

3

Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.COVID-19 住院高危患者中治疗剂量肝素与标准预防剂量或中剂量肝素预防血栓的疗效和安全性：HEP-COVID 随机临床试验。

JAMA Intern Med. 2021 Dec 1;181(12):1612-1620. doi: 10.1001/jamainternmed.2021.6203.

4

Anticoagulation for COVID-19 Patients: A Bird's-Eye View.COVID-19 患者的抗凝治疗：鸟瞰。

Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211039288. doi: 10.1177/10760296211039288.

5

Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol.随机对照试验比较高剂量与低剂量低分子肝素在需要侵入性机械通气的严重 COVID-19 肺炎和凝血病住院患者中的疗效和安全性 (COVID-19 HD)：研究方案的结构化总结。

Trials. 2020 Jun 26;21(1):574. doi: 10.1186/s13063-020-04475-z.

6

Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.住院 COVID-19 患者的凝血病：治疗性抗凝与标准治疗作为对 COVID-19 大流行的快速反应的实用随机对照试验 (RAPID COVID COAG - RAPID 试验)：一项随机对照试验研究方案的结构化总结。

Trials. 2021 Mar 10;22(1):202. doi: 10.1186/s13063-021-05076-0.

7

[Thromboembolism and antithrombotic management in pregnancy].[妊娠期血栓栓塞与抗栓治疗]

Orv Hetil. 2011 May 22;152(21):815-21. doi: 10.1556/OH.2011.29121.

8

Pragmatic Recommendations for the Management of Anticoagulation and Venous Thrombotic Disease for Hospitalized Patients with COVID-19 in Low- and Middle-Income Countries.中低收入国家 COVID-19 住院患者抗凝和静脉血栓疾病管理的实用建议。

Am J Trop Med Hyg. 2021 Jan 11;104(3_Suppl):99-109. doi: 10.4269/ajtmh.20-1305.

9

Guideline update. VTE disease: which agents, and when.指南更新。静脉血栓栓塞性疾病：使用哪些药物，何时使用。

J Fam Pract. 2009 Mar;58(3):E1.

10

The Impact of Risk-Adjusted Heparin Regimens on the Outcome of Patients with COVID-19 Infection. A Prospective Cohort Study.风险调整肝素方案对 COVID-19 感染患者结局的影响。一项前瞻性队列研究。

Viruses. 2021 Aug 30;13(9):1720. doi: 10.3390/v13091720.

引用本文的文献

1

Pulmonary embolism prophylaxis and treatment: What's right, what's wrong, and the future.肺栓塞的预防与治疗：正误与未来

Chin Med J Pulm Crit Care Med. 2025 Mar 10;3(1):1-5. doi: 10.1016/j.pccm.2025.02.003. eCollection 2025 Mar.